- What is Omrix Biopharmaceuticals' primary focus?
- Omrix Biopharmaceuticals specializes in the development and manufacture of products derived from human plasma, including biosurgical hemostatic products and passive immunotherapy products.
- When was Omrix Biopharmaceuticals founded?
- Omrix Biopharmaceuticals was founded in June 1995.
- How many employees does Omrix Biopharmaceuticals have?
- Omrix Biopharmaceuticals has 201-500 employees.
- What is the total amount of funding Omrix Biopharmaceuticals has raised?
- Omrix Biopharmaceuticals has raised a total of $4,840,000.
- When was Omrix Biopharmaceuticals' last funding round and who were the investors?
- Omrix Biopharmaceuticals' last funding round was in March 2005, with investors including Catalyst and Hercules Capital, Inc.
- What is the current status of Omrix Biopharmaceuticals?
- Omrix Biopharmaceuticals was acquired by Johnson & Johnson in November 2008 and operates as part of Johnson & Johnson's Medical Device and Diagnostics Sector, reporting through Ethicon Inc.
- Where are Omrix Biopharmaceuticals' facilities located?
- Omrix Biopharmaceuticals has a production plant at Tel Hashomer Hospital, a biomanufacturing facility in Har-Hozvim Technology Park, Jerusalem, and an R&D facility in the Weizmann Science Park of Ness Ziona.
- What types of products does Omrix Biopharmaceuticals offer?
- Omrix Biopharmaceuticals offers biosurgical products for controlling bleeding during surgery and passive immunotherapy products for patients with immune deficiencies.